Abstracts tagged "methotrexate (MTX) and psoriatic arthritis"

Abstract Number: 693 • 2018 ACR/ARHP Annual Meeting
Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 694 • 2018 ACR/ARHP Annual Meeting
Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Rochelle Castillo¹, Khushboo Sheth² and Santhanam Lakshminarayanan³, ¹University of Connecticut, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…
Abstract Number: 2865 • 2015 ACR/ARHP Annual Meeting
Methotrexate and Leflunomide Survival in Patients with Psoriatic Arthritis
Margarita Landi¹, Cecilia Zaffarana¹, Osvaldo Luis Cerda¹, Josefina Gallino Yanzi¹, Emilce Schneeberger¹, Ignacio Carrillo¹, María del Carmen Gonzalez Guzmán¹, Jose A Maldonado Cocco¹ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Disease Modifying Anti-Rheumatic Drugs (DMARDs) are frequently used in Psoriatic Arthritis (PsA), however there is limited data regarding their survival rates. This study attempts…
Abstract Number: 343 • 2013 ACR/ARHP Annual Meeting
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Elisabeth Lie¹, Karen M. Fagerli¹, Erik Rødevand², Synnøve Kalstad³, Knut Mikkelsen⁴, Ada Wierød⁵, Désirée van der Heijde⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ³Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁴Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital Drammen, Drammen, Norway, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Methotrexate (MTX), sulfasalazine (SSZ) and leflunomide (LEF) are recommended treatments for PsA patients with active peripheral arthritis. In the publication of a recent negative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].